Your browser doesn't support javascript.
Incidence of acute lower respiratory tract disease hospitalisations, including pneumonia, among adults in Bristol, UK, 2019, estimated using both a prospective and retrospective methodology.
Hyams, Catherine; Begier, Elizabeth; Garcia Gonzalez, Maria; Southern, Jo; Campling, James; Gray, Sharon; Oliver, Jennifer; Gessner, Bradford D; Finn, Adam.
  • Hyams C; Academic Respiratory Unit, University of Bristol, Bristol, UK catherine.hyams@bristol.ac.uk.
  • Begier E; Bristol Vaccine Centre, University of Bristol, Bristol, UK.
  • Garcia Gonzalez M; Global Medical and Scientific Affairs, Pfizer Inc, New York City, New York, USA.
  • Southern J; Population Health Sciences, University of Bristol, Bristol, UK.
  • Campling J; Academic Respiratory Unit, Southmead Hospital, Bristol, UK.
  • Gray S; Vaccines Medical Affairs, Pfizer Ltd, Tadworth, Surrey, UK.
  • Oliver J; Vaccines Medical Affairs, Pfizer Ltd, Tadworth, Surrey, UK.
  • Gessner BD; Global Medical and Scientific Affairs, Pfizer Inc, New York City, New York, USA.
  • Finn A; Bristol Vaccine Centre, University of Bristol, Bristol, UK.
BMJ Open ; 12(6): e057464, 2022 06 15.
Article in English | MEDLINE | ID: covidwho-1901997
ABSTRACT

OBJECTIVES:

To determine the disease burden of acute lower respiratory tract disease (aLRTD) and its subsets (pneumonia, lower respiratory tract infection (LRTI) and heart failure) in hospitalised adults in Bristol, UK.

SETTING:

Single-centre, secondary care hospital, Bristol, UK.

DESIGN:

We estimated aLRTD hospitalisations incidence in adults (≥18 years) in Bristol, UK, using two approaches. First, retrospective International Classification of Diseases 10th revision (ICD-10) code analysis (first five positions/hospitalisation) identified aLRTD events over a 12-month period (March 2018 to February 2019). Second, during a 21-day prospective review (19 August 2019 to 9 September 2019), aLRTD admissions were identified, categorised by diagnosis and subsequently annualised. Hospital catchment denominators were calculated using linked general practice and hospitalisation data, with each practice's denominator contribution calculated based on practice population and per cent of the practices' hospitalisations admitted to the study hospital.

PARTICIPANTS:

Prospective review 1322 adults screened; 410 identified with aLRTD. Retrospective review 7727 adult admissions. PRIMARY AND SECONDARY OUTCOME

MEASURES:

The incidence of aLRTD and its subsets in the adult population of Southmead Hospital, Bristol UK.

RESULTS:

Based on ICD-10 code analysis, annual incidences per 100 000 population were aLRTD, 1901; pneumonia, 591; LRTI, 739; heart failure, 402. aLRTD incidence was highest among those ≥65 years 65-74 (3684 per 100 000 adults), 75-84 (6962 per 100 000 adults) and ≥85 (11 430 per 100 000 adults). During the prospective review, 410/1322 (31%) hospitalised adults had aLRTD signs/symptoms and annualised incidences closely replicated retrospective analysis results.

CONCLUSIONS:

The aLRTD disease burden was high, increasing sharply with age. The aLRTD incidence is probably higher than estimated previously due to criteria specifying respiratory-specific symptoms or radiological change, usage of only the first diagnosis code and mismatch between case count sources and population denominators. This may have significant consequences for healthcare planning, including usage of current and future vaccinations against respiratory infection.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia / Respiration Disorders / Respiratory Tract Infections / Heart Failure Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Adult / Humans Country/Region as subject: Europa Language: English Journal: BMJ Open Year: 2022 Document Type: Article Affiliation country: Bmjopen-2021-057464

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia / Respiration Disorders / Respiratory Tract Infections / Heart Failure Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Adult / Humans Country/Region as subject: Europa Language: English Journal: BMJ Open Year: 2022 Document Type: Article Affiliation country: Bmjopen-2021-057464